Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Knockout Mouse Project Would Target 500 New Lines Annually

This article was originally published in The Pink Sheet Daily

Executive Summary

The advantages of such an effort would include “efficient production with reduced costs; uniform use of knockout methods, allowing for more comparability between knockout mice; and ready access to mice, their derivatives and data,” the group behind the proposed project predicts.

You may also be interested in...



Nexavar “Very Competitive” With Pfizer’s Sutent, Bayer Says

Bayer’s kidney cancer drug brought in $25.2 mil. (€20 mil.) in the first quarter following its approval late last year.

Nebivolol Approval Could Come In Mid-2007, Forest Says

The firm is conducting small studies of short duration after meeting with FDA regarding a May 2005 “approvable” letter.

Akorn’s Inapsine Set To Return To U.S. Market In June

The company has inked a hospital supply contract for the anesthetic droperidol.

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel